Cleveland BioLabs Announces Annual Meeting
(firmenpresse) - BUFFALO, NY -- (Marketwired) -- 02/10/15 -- (NASDAQ: CBLI) today announced that the Company will hold its 2015 Annual Meeting of Stockholders on April 14, 2015 in Buffalo, NY for stockholders of record as of March 5, 2015. The Company will distribute proxy materials to all eligible stockholders.
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are entolimod, which is being developed as radiation countermeasure and a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at .
Contact:
Rachel Levine
Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (917) 375-2935
E:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.02.2015 - 12:00 Uhr
Sprache: Deutsch
News-ID 370339
Anzahl Zeichen: 0
contact information:
Town:
BUFFALO, NY
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cleveland BioLabs Announces Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Cleveland BioLabs, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
